VESELA TZONEVA-KAMBEROVA: Open Payments
NPI 1356436794 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$405 in 19 payments from 8 companies in 2025. Trend: 2023 $143 · 2024 $169 · 2025 $405
Food & beverage: $405
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| Neurocrine BioSciences, Inc. | 4 | $82 |
| Alkermes, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Ethicon US, LLC | 1 | $40 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: AUSTEDO XR, INGREZZA, ARISTADA, VISTASEAL, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, COBENFY.
Industry payments across LA — which companies pay providers there.
